Skip to Content

Kimberly-Clark Corp KMB Stock Quote

| Rating as of

Morningstar‘s Stock Analysis KMB

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Skyrocketing Costs Eat Away at Kimberly-Clark's Near-term Profits, But Competitive Edge Unwavering

Erin Lash, CFA Sector Director

Business Strategy and Outlook

| Erin Lash, CFA |

From our vantage point, narrow-moat Kimberly-Clark continues to struggle navigating a volatile demand environment and pronounced cost pressures. While we didn't anticipate the significant level of consumer stock-ups realized since the onset of coronavirus would persist (particularly as mobility restrictions ease), commodity cost inflation has outpaced our expectations (serving as an 800-basis-point drag to gross margins in the second quarter), and these pressures are unlikely to abate. In this context, Kimberly expects inflation in the range of $1.4 billion to $1.6 billion in fiscal 2022, on top of the $1.5 billion in incremental costs incurred in fiscal 2021.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics KMB

Company Profile KMB

Business Description

With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.

Contact
P.O. Box 619100
Dallas, TX, 75261-9100
T +1 972 281-1200
Industry Household & Personal Products
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 45,000

Related News KMB